Brain tumors are the most common solid tumors in children and remain a significant contributor to death by disease in this population. Pediatric brain tumors (PBT) are broadly classified into two major categories: glial and neuronal tumors. Various factors, including tumor histology, tumor location, and demographics, influence the incidence and prognosis of this heterogeneous group of neoplasms. Numerous epidemiologic studies have been conducted to identify genetic and environmental risk factors for these malignancies. Thus far, the only established risk factors for PBTs are exposure to ionizing radiation and some rare genetic syndromes. However, relatively consistent evidence of positive associations for birth defects, markers of fetal growth, advanced parental age, maternal dietary N-nitroso compounds, and exposure to pesticides have been reported. The genetic variants associated with susceptibility to PBTs were predominantly identified by a candidate-gene approach. The identified genetic variants belong to four main pathways, including xenobiotic detoxification, inflammation, DNA repair, and cell-cycle regulation. Conducting large and multi-institutional studies is warranted to systematically detect genetic and environmental risk factors for different histologic subtypes of PBTs. This, in turn, might lead to a better understanding of etiology of PBTs and eventually developing risk prediction models to prevent these clinically significate malignancies.

Primary brain tumors are the most common solid tumors in children and the leading cause of cancer mortality in this population, in high-income countries. Pediatric brain tumors (PBT) are heterogeneous in histopathology, molecular features, and prognosis, and they are classified into two major categories including glial and neuronal tumors (1). The most common forms of glioma in children are astrocytomas, oligodendrogliomas, ependymomas, brain stem gliomas, and optic nerve gliomas. Another rare, but often fatal glial tumor that occurs in children is diffuse intrinsic pontine glioma, or DIPG. The majority of neuronal tumors are embryonal tumors of which the most common types are: medulloblastoma, atypical teratoid/rhabdoid tumors, and central nervous system primitive neuroectodermal tumors (CNS PNET; refs. 2, 3). The term PNET was removed with the 2016 World Health Organization Classification of CNS tumors (3). The new classification is based on amplification of the C19MC region on chromosome 19 (19q13.42). Embryonal tumors with abundant neuropil and true rosettes, ependymoblastomas, and some medulloepithelioma were reclassified as embryonal tumor with multilayered rosettes C19MC-altere. Without C19MC amplification, they should be classified as embryonal tumor with multilayered rosettes, NOS (not otherwise specified) or medulloepithelioma, depending on their histologic features. The term CNS embryonal tumor, NOS is used for CNS PNETs without classifiable genetic mutations (3). Table 1 summarizes the most commonly occurring brain tumor histologies in children (3, 4).

The frequency of different histologic subtypes of PBTs varies by age. According to the Central Brain Tumor Registry of the United States (CBTRUS), in children 0–14 years old, glioma accounted for 53% of all primary brain and other CNS tumors. Among gliomas, the majority were pilocytic astrocytoma (33%) followed by other low-grade gliomas (27%). In addition, 15% of all primary CNS tumors were embryonal tumors of which medulloblastoma (62%) and atypical teratoid/rhabdoid tumors (15%) were the most common histologic subtypes (5).

Incidence and prognosis of PBTs varies greatly and depends on various factors including tumor histology, tumor location, age at diagnosis, race, ethnicity, and sex. Despite their prevalence and clinical importance, knowledge on the etiology and molecular characterizations of pediatric brain tumors is limited. In this review article, serving as an update to the review article by Johnson and colleagues (6), we summarize the descriptive epidemiology and the current knowledge on etiology of primary pediatric brain tumors.

Incidence

The incidence of PBTs differs by age, sex, geography, race, and ethnicity. In the United States, from 2012 to 2016, the incidence of all primary brain and other CNS tumors in children and adolescents <20 years of age was 6.06 per 100,000 children. Approximately, 58% of cases were malignant and 42% were nonmalignant (4). The incidence was reported to be higher in non-Hispanics compared with Hispanics (6.35 vs. 5.14 per 100,000) as well as in Whites compared with Blacks (6.29 vs. 4.71 per 100,000). The largest differences were observed in incidence of neuroepithelial tissue tumors and cranial and spinal nerves tumors between non-Hispanics and Hispanics, while between Blacks and Whites, the largest differences were found in incidence of neuroepithelial tissue tumors, cranial, spinal nerves tumors, germ cell tumors, and tumors of sellar region (4). In addition, the incidence of all primary brain and other CNS tumors was higher in girls compared with boys (6.13 vs. 5.98 per 100,000; ref. 4); however, this is not consistent with previous reports indicating higher incidence for most histologies in boys compared with girls (5.44 vs. 5.07 per 100,000; for all brain and CNS tumors), during 2007–2011 in the United States (5). The observed elevated incidence for all primary brain and other CNS tumors in girls might be driven by meningioma in 15–19 years old females that were not included in the previous studies, reported on the basis of 0–14 years old children. Among other histologies, medulloblastoma was more common in males compared with girls (0.60 vs. 0.38 per 100,000; ref. 5). According to the CBTRUS report, among children 0–4 years of age diagnosed with brain and other CNS tumors, the highest incidence was attributable to pilocytic astrocytomas (1.15 per 100,000); however, the incidence of this histologic subtype decreased with advancing age. Among children ages 5–9, pilocytic astrocytoma (1.04 per 100,000) followed by malignant glioma (0.88 per 100,000) showed the highest incidence. In addition, the highest incidence of medulloblastoma was observed among children 5–9 years of age (0.59 per 100,000). Among children ages 10–14 and 15–19, the highest incidence was attributable to tumors of the sellar region (0.86 per 100,000) and tumors of the pituitary (2.30 per 100,000), respectively (4).

Survival for patients with PBTs also varies by histology, tumor location, age at diagnosis, race, and ethnicity. The 10-year survival for children ages 0–19 diagnosed with malignant brain and other CNS tumors was estimated at 72% with lowest (17%) and highest (96%) survival rates being attributable to glioblastoma and pilocytic astrocytoma, respectively. In addition, in the United States, 96% of children 0–19 years old with nonmalignant tumors survived 10 years after diagnosis (4). Overall, tumors located in the brain stem showed the poorest survival compared with tumors located at any other site, while tumors of the cranial nerves showed the highest survival (5). Also, survival is better for children diagnosed at an older age, because younger children cannot be treated as intensively as older children (1, 5). Therefore, the difference in survival by age is more pronounced for medulloblastoma and PNETs because their treatment depends more on radiotherapy (5). Survival was reported to be poorer among non-Hispanic Blacks and Hispanic patients compared with non-Hispanic Whites (7–10); in the United States for the period of 2001–2008, 5-year relative survival was reported as 77.6% for non-Hispanic White patients, 69.8% for non-Hispanic Black patients, and 72.9% for Hispanic patients (7). In contrast, among adults ages 18 years or older, in the United States, during 2000–2014, the survival for many tumor types was reported to be poorer in non-Hispanic Whites, while it was relatively comparable in Hispanics and Blacks (11).

Known and suspected genetic risk factors

Cancer predisposition syndromes

There is an established increased risk of PBTs associated with rare single-gene disorders or genetic syndromes, which may occur de novo or may be inherited. However, only a small proportion (∼4%) of PBTs are attributable to these rare autosomal dominant or autosomal recessive disorders. The most common genetic syndromes (and their related genes) predisposing to nervous system tumors include: neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), tuberous sclerosis complex (TSC1 or TSC2), Li-Fraumeni (TP53), Gorlin syndrome (PTCH1), familial adenomatous polyposis (APC, MMR), glioma susceptibility 3 (BRCA2), and biallelic mismatch repair deficiency (MSH2, MLH1, MSH6, PMS2; refs. 12–14).

Family history

A modest risk of developing CNS tumors among the siblings of PBT cases has been reported. In particular, a higher risk was observed if both children have been diagnosed with medulloblastoma and PNET. Children with a parent diagnosed with a CNS tumor showed an elevated risk of developing brain tumors; however, these observed associations were based on small numbers of affected families. In general, there is limited evidence for an association between family history of cancer and nonsyndromic PBTs (6, 15).

Rare variants

Because of rarity of PBTs and further rarity of familial PBTs, little knowledge is available on genetic variants contributing to the genetic architecture of familial PBTs. Backes and colleagues (16) performed a study in a family with two unaffected parents and two siblings diagnosed with glioblastoma. By using whole-exome sequencing, they identified three significant pathways containing at least three affected genes, including: focal adhesion, extracellular matrix–receptor interaction, and complement and coagulation cascades. Of all the identified genes, 32 genes were located on chromosomes 1, 11, and 22. More specifically, the affected genes were accumulated on 22q12.2 and 1p36.33 (16).

Germline mutations associated with sporadic PBTs vary by histologic subtype, and about 10% of sporadic PBT cases harbor a predisposition mutation. To date, the conducted studies have been mainly focused on high-penetrant germline mutations in known cancer predisposition genes; therefore, the contribution of rare high-penetrant mutations in the risk of PBTs is largely unknown (17). Recently, a large study, performed on childhood high-grade glioma by using whole-exome sequencing, identified that the rare germline variants associated with risk of PBTs are mainly located in 24 genes largely involved in DNA repair and cell-cycle pathways, predominantly in the TP53 and NF1 genes (18). In addition, Waszak and colleagues, by employing rare variant burden analysis, estimated that 6% of medulloblastoma diagnoses are attributable to germline mutations and identified APC, BRCA2, PALB2, PTCH1, SUFU, and TP53 as consensus medulloblastoma predisposition genes. They reported that the prevalence of genetic predispositions differs among molecular subgroups of medulloblastoma, with the highest prevalence being attributable to patients in the Sonic HedgeHog (SHH) subgroup. Also, correlations between specific germline mutations and development of specific molecular subgroups of medulloblastoma were detected (19). Furthermore, they identified ELP1 as the most common medulloblastoma predisposition gene and found that ELP1 rare variants occurred in 14% of medulloblastoma SHH subgroup and elevated the prevalence of genetic predisposition to 40% among patients in this molecular subgroup (20). Begemann and colleagues, by investigating 1,044 medulloblastoma cases, identified that heterozygous germline mutations in the G protein–coupled receptor 161 (GPR161) gene was exclusively associated with SHH subgroup and accounted for 5% of infants with SHH subgroup in their medulloblastoma cohort (21).

Common genetic variants and sporadic brain tumors

Very few and generally small genetic association studies have been conducted on brain tumors in children and adolescents. To date, there is one published genome-wide association study (GWAS) of medulloblastoma. This study identified 13 genetic variants associated with medulloblastoma risk located in CD83 (6p23), MAGI2 (7q21.11), CSMD1 (8p23.2), DOCK1 (10q26.2), PTPRM (18p11.23), and 8q24.12 (22). The genetic variants associated with risk of PBTs have been mainly identified by candidate-gene association studies conducted on pooled histologic subtypes of PBTs (12). The identified genetic variants mainly belong to genes involved in xenobiotic detoxification (CYP1A1, GSTT1, GSTM1; refs. 23, 24), inflammation (NOS1; ref. 24), DNA repair (ERCC1, ERCC2, CHAF1A, XRCC1, EME1, ATM, GLTSCR1, XRCC4, PALB2; refs. 22, 24–26), and cell-cycle regulation (AICDA, CASP1, IRS2, EGFR, PTCH1; refs. 22, 25–27). It has been shown that the validated genetic variants identified by GWAS on adult glioma are also associated with risk of PBTs. These variants are predominantly located in TERT (5p15.33), RTEL1 (20q13.33), CCDC26 (8q24.21), and CDKN2BAS (9p21.3; refs. 28–30). A recent study was performed in a U.S. population to assess whether genome-wide ancestry differences are associated with risk of ependymoma. In addition, admixture mapping was conducted to detect associations with local ancestry. The results revealed significant associations between eastern European ancestral substructure and ependymoma risk among Hispanics and non-Hispanic Whites. Furthermore, a significant peak located at 20p13 was detected to be associated with increased local European ancestry (31). Given the limited knowledge available on the germline variants associated with PBTs and the rarity of these malignancies, utilizing various approaches, including Mendelian randomization, are needed for a better understanding of the etiology of PBTs and assessing their risk factors (32). Table 2 summarizes the identified genetic variants associated with PBT risk.

Maternal genetic effect

Despite the potentially important role of maternal genetics on the risk of PBTs by affecting the in utero environment of the developing embryo, limited knowledge is available on role of maternal genetic variations in the etiology of these tumors. Lupo and colleagues (33), in the only available study of its kind, investigated the role of maternal variation in xenobiotic detoxification genes and the risk of pediatric medulloblastoma using a case-parent triad study design. The results indicated that maternal variation in EPHX1 (rs1051740) was associated with elevated risk of pediatric medulloblastoma (relative risk = 3.26; 95% confidence interval, 1.12–9.53; ref. 33).

Known and suspected nongenetic risk factors

Ionizing radiation

Exposure to moderate-to-high doses of ionizing radiation is the only established environmental risk factor for PBTs (34). Compared with adults, children are more radiosensitive and have a longer life expectancy to experience the carcinogenic effects of ionizing radiation (35). There is evidence that radiotherapy for early-onset childhood cancers, particularly children who received radiotherapy for acute lymphoblastic leukemia that included exposure to the brain, is correlated with an increased risk of brain tumor development later in life (12, 34, 36). In addition, some studies have reported that maternal diagnostic radiation during pregnancy is associated with an increased risk of brain tumors in offspring (34, 37). The effect of diagnostic radiation during early childhood on subsequent brain tumor risk was evaluated, and a 29% excess risk was reported for children exposed to one or more head CT scans (35, 37–39). This finding should be interpreted with caution because pre-existing cancer in children with high susceptibility may lead to undergoing more head CT scans (39).

Non-ionizing radiation

The effects of non-ionizing radiation, including radiofrequency, microwaves, and extremely low-frequency (ELF) magnetic fields, on the risk of PBTs have been investigated by some studies. Despite the classification of radiofrequency fields as a possible carcinogen by the International Agency for Research on Cancer (IARC) in 2011, no significant associations were observed for cellular phone use or other radiofrequency radiation exposure by recent high-quality studies. In addition, in 2002, based on the available findings, IARC concluded that there are not sufficient data to classify ELFs as a risk factor for brain tumors (6, 12).

Allergic conditions

Although there is consistent evidence for an association between personal medical history of allergies and decreased risk of adult glioma, inconsistent evidence of reduced risk of PBTs associated with allergic and atopic conditions (such as asthma, wheezing, and eczema), as well as early life exposure to infections, has been reported previously (6, 40–42). It is unclear whether history of allergies and atopic diseases decrease the risk of PBTs or PBTs prevents allergic and atopic conditions, further investigations are warranted to clarify the action of these effects (42).

Parental factors

Advanced parental age, as a marker for accumulated genetic aberrations in the parents' DNA, has been reported to be associated with an elevated risk of brain tumors in offspring (43). There is more consistent evidence of increased risk of PBTs associated with advanced paternal age at birth than advanced maternal age at birth (6, 44). Despite the extensive research on the association between parental occupational exposures and risk of brain tumors in offspring, inconsistent findings have been reported. However, the results from the studies of parental occupational/residential exposure to pesticides are more consistent and the meta-analysis studies indicate a positive association between risk of PBTs and exposure to pesticides (6, 12, 45, 46). In addition, positive associations between parental high socioeconomic status (47, 48) as well as maternal intake of dietary N-nitroso compounds (NOC) and risk of PBTs in offspring have been reported by meta-analysis (6, 12, 49).

Birth characteristics and structural birth defects

Of the investigated birth characteristics, large studies and meta-analyses provide evidence that high birth weight (>4,000 g) is associated with an increased risk of pediatric CNS tumors, particularly astrocytoma and embryonal tumors (50, 51).

Approximately 7% of PBTs can be attributable to nonchromosomal structural birth defects, which is one of the most consistent risk factors for childhood cancer overall (12, 52). Large, population-based studies reported that birth defects are associated with approximately 2-fold elevated risk of brain tumors in children. (12, 53, 54). Children with CNS birth defects or with a neurologic anomalies showed an even higher susceptibility to developing PBTs (12, 55). Table 3 summarizes the suspected nongenetic risk factors associated with PBT risk.

PBTs represent a complex heterogeneous group of neoplasms with different histopathology, molecular features, and etiology. Various factors including tumor histology, tumor location, age at diagnosis, sex, race, and ethnicity are correlated with the incidence and prognosis of PBTs. Exposure to ionizing radiation and some rare genetic syndromes are the only established risk factors for PBTs; although relatively consistent evidence of positive associations for birth defects, markers of fetal growth, advanced parental age, maternal dietary NOCs, and exposure to pesticide has been reported (summarized in Fig. 1); however, the findings of these studies should be interpreted with caution as some of the studies are based on small sample sizes and exhibit some methodologic challenges.

Performing large, collaborative, and multi-institutional genetic studies based on SNP-array and next-generation sequencing data to identify common and rare germline variants associated with risk of PBTs, in different ethnic groups, is an important research priority. Considering the heterogeneity of PBTs, the studies that aim to evaluate histology-specific risk variants are also needed. Utilizing high-quality publicly available genetic and environmental data as well as data from cancer and birth defect registries are beneficial for studies of these rare tumors. Gene–environment interaction studies will play an important role to increase our understanding of the etiology of PBTs. Incorporating genetic and environmental data may lead to the development of comprehensive risk prediction models that could be leveraged for the prevention of these tumors. To conclude, the literature on the risk factors for PBTs is currently an amalgam of small, underpowered studies, many of which also suffer design flaws that limit their generalizability. As such, the PBT etiologic literature suffers from extensive publication bias. Thus, large-scale, well-powered systematic collaborative studies conducted by researchers from multiple institutions are warranted in the pediatric brain tumor research field to improve our knowledge of PBT risk factors; which would lead to the development of prevention measures and better management of pediatric brain tumors.

M. Adel Fahmideh reports grants from Cancer Prevention and Research Institute of Texas during the conduct of the study. No disclosures were reported by the other authors.

The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; or decision to submit the article for publication.

This study was supported, in part, by the Research Training Award for Cancer Prevention Post-Graduate Training Program in Integrative Epidemiology from the Cancer Prevention and Research Institute of Texas (grant number RP160097, PI: M. Spitz).

1.
Pollack
IF
,
Jakacki
RI
. 
Childhood brain tumors: epidemiology, current management and future directions
.
Nat Rev Neurol
2011
;
7
:
495
506
.
2.
Pfister
S
,
Hartmann
C
,
Korshunov
A
. 
Histology and molecular pathology of pediatric brain tumors
.
J Child Neurol
2009
;
24
:
1375
86
.
3.
Louis
DN
,
Perry
A
,
Reifenberger
G
,
von Deimling
A
,
Figarella-Branger
D
,
Cavenee
WK
, et al
The 2016 World Health Organization classification of tumors of the central nervous system: a summary
.
Acta Neuropathol
2016
;
131
:
803
20
.
4.
Ostrom
QT
,
Cioffi
G
,
Gittleman
H
,
Patil
N
,
Waite
K
,
Kruchko
C
, et al
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016
.
Neuro Oncol
2019
;
21
:
v1
v100
.
5.
Ostrom
QT
,
de Blank
PM
,
Kruchko
C
,
Petersen
CM
,
Liao
P
,
Finlay
JL
, et al
Alex's lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011
.
Neuro Oncol
2015
;
16
:
x1
x36
.
6.
Johnson
KJ
,
Cullen
J
,
Barnholtz-Sloan
JS
,
Ostrom
QT
,
Langer
CE
,
Turner
MC
, et al
Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review
.
Cancer Epidemiol Biomarkers Prev
2014
;
23
:
2716
36
.
7.
Siegel
DA
,
Li
J
,
Ding
H
,
Singh
SD
,
King
JB
,
Pollack
LA
. 
Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States
.
Pediatr Blood Cancer
2019
;
66
:
e27501
.
8.
Austin
MT
,
Hamilton
E
,
Zebda
D
,
Nguyen
H
,
Eberth
JM
,
Chang
Y
, et al
Health disparities and impact on outcomes in children with primary central nervous system solid tumors
.
J Neurosurg Pediatr
2016
;
18
:
585
93
.
9.
Holmes
L
 Jr.
,
Chavan
P
,
Blake
T
,
Dabney
K
. 
Unequal cumulative incidence and mortality outcome in childhood brain and central nervous system malignancy in the USA
.
J Racial Ethn Health Disparities
2018
;
5
:
1131
41
.
10.
Cooney
T
,
Fisher
PG
,
Tao
L
,
Clarke
CA
,
Partap
S
. 
Pediatric neuro-oncology survival disparities in California
.
J Neurooncol
2018
;
138
:
83
97
.
11.
Ostrom
QT
,
Cote
DJ
,
Ascha
M
,
Kruchko
C
,
Barnholtz-Sloan
JS
. 
Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014
.
JAMA Oncol
2018
;
4
:
1254
62
.
12.
Ostrom
QT
,
Adel Fahmideh
M
,
Cote
DJ
,
Muskens
IS
,
Schraw
JM
,
Scheurer
ME
, et al
Risk factors for childhood and adult primary brain tumors
.
Neuro Oncol
2019
;
21
:
1357
75
.
13.
Durno
CA
,
Sherman
PM
,
Aronson
M
,
Malkin
D
,
Hawkins
C
,
Bakry
D
, et al
Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome
.
Eur J Cancer
2015
;
51
:
977
83
.
14.
Reid
S
,
Renwick
A
,
Seal
S
,
Baskcomb
L
,
Barfoot
R
,
Jayatilake
H
, et al
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour
.
J Med Genet
2005
;
42
:
147
51
.
15.
Dearlove
JV
,
Fisher
PG
,
Buffler
PA
. 
Family history of cancer among children with brain tumors: a critical review
.
J Pediatr Hematol Oncol
2008
;
30
:
8
14
.
16.
Backes
C
,
Harz
C
,
Fischer
U
,
Schmitt
J
,
Ludwig
N
,
Petersen
BS
, et al
New insights into the genetics of glioblastoma multiforme by familial exome sequencing
.
Oncotarget
2015
;
6
:
5918
31
.
17.
Muskens
IS
,
Zhang
C
,
de Smith
AJ
,
Biegel
JA
,
Walsh
KM
,
Wiemels
JL
. 
Germline genetic landscape of pediatric central nervous system tumors
.
Neuro Oncol
2019
;
21
:
1376
88
.
18.
Muskens
IS
, de
Smith
AJ
,
Zhang
C
,
Hansen
HM
,
Morimoto
L
,
Metayer
C
, et al
Germline cancer predisposition variants and pediatric glioma: a population-based study in California
.
Neuro Oncol
2020
;
22
:
864
74
.
19.
Waszak
SM
,
Northcott
PA
,
Buchhalter
I
,
Robinson
GW
,
Sutter
C
,
Groebner
S
, et al
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
.
Lancet Oncol
2018
;
19
:
785
98
.
20.
Waszak
SM
,
Robinson
GW
,
Gudenas
BL
,
Smith
KS
,
Forget
A
,
Kojic
M
, et al
Germline Elongator mutations in Sonic Hedgehog medulloblastoma
.
Nature
2020
;
580
:
396
401
.
21.
Begemann
M
,
Waszak
SM
,
Robinson
GW
,
Jager
N
,
Sharma
T
,
Knopp
C
, et al
Germline GPR161 mutations predispose to pediatric medulloblastoma
.
J Clin Oncol
2020
;
38
:
43
50
.
22.
Dahlin
AM
,
Wibom
C
,
Andersson
U
,
Bybjerg-Grauholm
J
,
Deltour
I
,
Hougaard
DM
, et al
A genome-wide association study on medulloblastoma
.
J Neurooncol
2020
;
147
:
309
15
.
23.
Salnikova
LE
,
Belopolskaya
OB
,
Zelinskaya
NI
,
Rubanovich
AV
. 
The potential effect of gender in CYP1A1 and GSTM1 genotype-specific associations with pediatric brain tumor
.
Tumour Biol
2013
;
34
:
2709
19
.
24.
Salnikova
LE
,
Zelinskaya
NI
,
Belopolskaya
OB
,
Aslanyan
MM
,
Rubanovich
AV
. 
Association study of xenobiotic detoxication and repair genes with malignant brain tumors in children
.
Acta Naturae
2010
;
2
:
58
65
.
25.
Jeon
S
,
Han
S
,
Lee
K
,
Choi
J
,
Park
SK
,
Park
AK
, et al
Genetic variants of AICDA/CASP14 associated with childhood brain tumor
.
Genet Mol Res
2013
;
12
:
2024
31
.
26.
Adel Fahmideh
M
,
Lavebratt
C
,
Schuz
J
,
Roosli
M
,
Tynes
T
,
Grotzer
MA
, et al
Common genetic variations in cell cycle and DNA repair pathways associated with pediatric brain tumor susceptibility
.
Oncotarget
2016
;
7
:
63640
50
.
27.
Baocheng
W
,
Zhao
Y
,
Meng
W
,
Han
Y
,
Wang
J
,
Liu
F
, et al
Polymorphisms of insulin receptor substrate 2 are putative biomarkers for pediatric medulloblastoma: considering the genetic susceptibility and pathological diagnoses
.
Nagoya J Med Sci
2017
;
79
:
47
54
.
28.
Adel Fahmideh
M
,
Lavebratt
C
,
Schuz
J
,
Roosli
M
,
Tynes
T
,
Grotzer
MA
, et al
CCDC26, CDKN2BAS, RTEL1 and TERT polymorphisms in pediatric brain tumor susceptibility
.
Carcinogenesis
2015
;
36
:
876
82
.
29.
Adel Fahmideh
M
,
Lavebratt
C
,
Tettamanti
G
,
Schuz
J
,
Roosli
M
,
Kjaerheim
K
, et al
A weighted genetic risk score of adult glioma susceptibility loci associated with pediatric brain tumor risk
.
Sci Rep
2019
;
9
:
18142
.
30.
Dahlin
AM
,
Wibom
C
,
Andersson
U
,
Hougaard
DM
,
Bybjerg-Grauholm
J
,
Deltour
I
, et al
Genetic variants in the 9p21.3 locus associated with glioma risk in children, adolescents, and young adults: a case-control study
.
Cancer Epidemiol Biomarkers Prev
2019
;
28
:
1252
8
.
31.
Zhang
C
,
Ostrom
QT
,
Hansen
HM
,
Gonzalez-Maya
J
,
Hu
D
,
Ziv
E
, et al
European genetic ancestry associated with risk of childhood ependymoma
.
Neuro Oncol
2020
;
22
:
1637
46
.
32.
Zhang
C
,
Ostrom
QT
,
Semmes
EC
,
Ramaswamy
V
,
Hansen
HM
,
Morimoto
L
, et al
Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma
.
Acta Neuropathol Commun
2020
;
8
:
173
.
33.
Lupo
PJ
,
Nousome
D
,
Okcu
MF
,
Chintagumpala
M
,
Scheurer
ME
. 
Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study
.
Pediatr Hematol Oncol
2012
;
29
:
679
85
.
34.
Baldwin
RT
,
Preston-Martin
S
. 
Epidemiology of brain tumors in childhood–a review
.
Toxicol Appl Pharmacol
2004
;
199
:
118
31
.
35.
Kleinerman
RA
. 
Cancer risks following diagnostic and therapeutic radiation exposure in children
.
Pediatr Radiol
2006
;
36
:
121
5
.
36.
Ohgaki
H
,
Kleihues
P
. 
Epidemiology and etiology of gliomas
.
Acta Neuropathol
2005
;
109
:
93
108
.
37.
Linet
MS
,
Kim
KP
,
Rajaraman
P
. 
Children's exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations
.
Pediatr Radiol
2009
;
39
:
S4
26
.
38.
Tettamanti
G
,
Shu
X
,
Adel Fahmideh
M
,
Schuz
J
,
Roosli
M
,
Tynes
T
, et al
Prenatal and postnatal medical conditions and the risk of brain tumors in children and adolescents: an international multicenter case-control study
.
Cancer Epidemiol Biomarkers Prev
2017
;
26
:
110
5
.
39.
Sheppard
JP
,
Nguyen
T
,
Alkhalid
Y
,
Beckett
JS
,
Salamon
N
,
Yang
I
. 
Risk of brain tumor induction from pediatric head CT procedures: a systematic literature review
.
Brain Tumor Res Treat
2018
;
6
:
1
7
.
40.
Lupatsch
JE
,
Bailey
HD
,
Lacour
B
,
Dufour
C
,
Bertozzi
AI
,
Leblond
P
, et al
Childhood brain tumours, early infections and immune stimulation: a pooled analysis of the ESCALE and ESTELLE case-control studies (SFCE, France)
.
Cancer Epidemiol
2018
;
52
:
1
9
.
41.
Andersen
TV
,
Schmidt
LS
,
Poulsen
AH
,
Feychting
M
,
Roosli
M
,
Tynes
T
, et al
Patterns of exposure to infectious diseases and social contacts in early life and risk of brain tumours in children and adolescents: an international case-control study (CEFALO)
.
Br J Cancer
2013
;
108
:
2346
53
.
42.
Shu
X
,
Prochazka
M
,
Lannering
B
,
Schuz
J
,
Roosli
M
,
Tynes
T
, et al
Atopic conditions and brain tumor risk in children and adolescents–an international case-control study (CEFALO)
.
Ann Oncol
2014
;
25
:
902
8
.
43.
Wang
R
,
Metayer
C
,
Morimoto
L
,
Wiemels
JL
,
Yang
J
,
DeWan
AT
, et al
Parental age and risk of pediatric cancer in the offspring: a population-based record-linkage study in California
.
Am J Epidemiol
2017
;
186
:
843
56
.
44.
Rios
L
,
Vasquez
L
,
Oscanoa
M
,
Maza
I
,
Geronimo
J
. 
Advancing parental age and risk of solid tumors in children: a case-control study in Peru
.
J Oncol
2018
;
2018
:
3924635
.
45.
Van Maele-Fabry
G
,
Gamet-Payrastre
L
,
Lison
D
. 
Residential exposure to pesticides as risk factor for childhood and young adult brain tumors: a systematic review and meta-analysis
.
Environ Int
2017
;
106
:
69
90
.
46.
Vidart d'Egurbide Bagazgoitia
N
,
Bailey
HD
,
Orsi
L
,
Lacour
B
,
Guerrini-Rousseau
L
,
Bertozzi
AI
, et al
Maternal residential pesticide use during pregnancy and risk of malignant childhood brain tumors: a pooled analysis of the ESCALE and ESTELLE studies (SFCE)
.
Int J Cancer
2018
;
142
:
489
97
.
47.
Erdmann
F
,
Hvidtfeldt
UA
,
Sorensen
M
,
Raaschou-Nielsen
O
. 
Socioeconomic differences in the risk of childhood central nervous system tumors in Denmark: a nationwide register-based case-control study
.
Cancer Causes Control
2020
;
31
:
915
29
.
48.
Francis
SS
,
Wang
R
,
Enders
C
,
Prado
I
,
Wiemels
JL
,
Ma
X
, et al
Socioeconomic status and childhood central nervous system tumors in California
.
Cancer Causes Control
2020
;
32
:
27
39
.
49.
Huncharek
M
,
Kupelnick
B
. 
A meta-analysis of maternal cured meat consumption during pregnancy and the risk of childhood brain tumors
.
Neuroepidemiology
2004
;
23
:
78
84
.
50.
Georgakis
MK
,
Kalogirou
EI
,
Liaskas
A
,
Karalexi
MA
,
Papathoma
P
,
Ladopoulou
K
, et al
Anthropometrics at birth and risk of a primary central nervous system tumour: a systematic review and meta-analysis
.
Eur J Cancer
2017
;
75
:
117
31
.
51.
Dahlhaus
A
,
Prengel
P
,
Spector
L
,
Pieper
D
. 
Birth weight and subsequent risk of childhood primary brain tumors: an updated meta-analysis
.
Pediatr Blood Cancer
2017
;
64
.
52.
Johnson
KJ
,
Lee
JM
,
Ahsan
K
,
Padda
H
,
Feng
Q
,
Partap
S
, et al
Pediatric cancer risk in association with birth defects: a systematic review
.
PLoS One
2017
;
12
:
e0181246
.
53.
Fisher
PG
,
Reynolds
P
,
Von Behren
J
,
Carmichael
SL
,
Rasmussen
SA
,
Shaw
GM
. 
Cancer in children with nonchromosomal birth defects
.
J Pediatr
2012
;
160
:
978
83
.
54.
Botto
LD
,
Flood
T
,
Little
J
,
Fluchel
MN
,
Krikov
S
,
Feldkamp
ML
, et al
Cancer risk in children and adolescents with birth defects: a population-based cohort study
.
PLoS One
2013
;
8
:
e69077
.
55.
Lupo
PJ
,
Schraw
JM
,
Desrosiers
TA
,
Nembhard
WN
,
Langlois
PH
,
Canfield
MA
, et al
Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births
.
JAMA Oncol
2019
;
5
:
1150
8
.